This educational activity provides a comprehensive overview of the mechanisms behind anti PD-1 resistance, the latest safety and efficacy data on oncolytic viruses, and their role in current treatment paradigms. Through expert-led discussions and case-based presentations, viewers gain critical insights to enhance their clinical practice and improve patient outcomes. This program is designed to help equip healthcare professionals with the necessary tools to effectively incorporate oncolytic virus therapies into their melanoma treatment strategies. Association Statement Provider Statement This continuing education activity is provided by Vindico Medical Education. Supporter Statement This activity is supported by an educational grant from Replimune, Inc. Overview Statement (Marketing) Pre/Post-Test Location \EgnyteDrivewyanokegroupSharedVMEActivityHematology_Oncology20242024 Replimune Melanoma SMR Mtg_End- H282, H2832024 Web-H283DeliverablesQuestion Mapping Grid_H283.docx Evaluation Location W:SharedVMEActivityHematology_Oncology20242024 Replimune Melanoma SMR Mtg_End- H282, H2832024 Web-H283DeliverablesH283-Evaluation.docx
- Provider:Vindico Medical Education, LLC
- Activity Link: https://www.healio.com/cme/oncologyce/melanoma/20241106/melanoma-and-oncolytic-virus-therapy-exploration-for-anti-pd-1-failure/overview
- Start Date: 2024-11-22 06:00:00
- End Date: 2024-11-22 06:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 0.75 hours
- Commercial Support: Source: Replimune, Inc. - Amount: 35142.5 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all